Therefore, we examine the relationship between NF-κB, Akt, IL6/JAK2/STAT3, and AICDA under EGFR-TKI treatment, and propose target markers for overcoming the EGFR-TKI resistance of NSCLC. The gene discussed is JAK2; the disease is non-small cell lung carcinoma.